Royalty Pharma has acquired PTC's remaining royalty on Roche's Evrysdi for $240 million upfront and sales-based milestones.

Biogen Inc. shares, despite retail investor pessimism, rose 15.1% in 2025. Besides the successful launch of Leqembi, I highlight Skyclarys, an Nrf2 activator for the treatment of Friedreich's ataxia, as a driver of Biogen's EBIT growth. Its sales totaled $132.9 million in Q3, up 29.9% year-over-year.

Assenagon Asset Management S.A. cut its position in Biogen Inc. (NASDAQ: BIIB) by 36.8% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 6,913 shares of the biotechnology company's stock after selling 4,023 shares during the period. Assenagon Asset Management

Thrivent Financial for Lutherans grew its position in shares of Biogen Inc. (NASDAQ: BIIB) by 24.2% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 18,195 shares of the biotechnology company's stock after buying an additional 3,544 shares during the

CAMBRIDGE, Mass., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – today announced that The Journal of the American Medical Association (JAMA) Neurology has published final results from the completed Phase 3 VALOR study and its open-label extension (OLE) study evaluating QALSODY® (tofersen) for the treatment of superoxide dismutase 1 (SOD1) amyotrophic lateral sclerosis (ALS) with over 3.5 years of follow-up. These results show that early initiation of QALSODY was associated with numerically slower decline in measures of clinical function, breathing and strength, as well as reduction in the risk of death or permanent ventilation. Sustained reductions in neurofilament, a marker of neurodegeneration, further validate the clinical results and demonstrate QALSODY's impact on the underlying biology of SOD1-ALS.

Corient Private Wealth LLC boosted its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 15.2% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 34,331 shares of the biotechnology company's stock after acquiring an additional 4,540 shares during the quarter.

The Nasdaq-100 Index has announced its annual reconstitution, with six new companies being added and six being removed, effective December 22, 2025.

Balyasny Asset Management L.P. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 5.8% in the undefined quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 831,905 shares of the biotechnology company's stock after purchasing an additional 45,686 shares during

Daiwa Securities Group Inc. lessened its holdings in Biogen Inc. (NASDAQ: BIIB) by 9.8% during the second quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 39,128 shares of the biotechnology company's stock after selling 4,265 shares during the quarter. Daiwa Securities Group Inc.'s holdings

Federated Hermes Inc. raised its holdings in shares of Biogen Inc. (NASDAQ: BIIB) by 16.5% in the undefined quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 120,277 shares of the biotechnology company's stock after purchasing an additional 17,069 shares during the quarter. Federated